ARTGEN THERAPEUTICS
Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101, is a DNA plasmid designed to stimulate angiogenesis with the first indication directed for Peripheral Artery Disease (PAD). ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis. Artgen's platform technology has the potential for treatment of other vascular diseases.
Similar Organizations
Anagin
Anagin is developing first-in-class therapies for treating neuropsychiatric diseases.
BELX BioPharma
develop botanical new drugs for treatments of tumors, chronic liver diseases and cancers
Bikam
Bikam developing novel therapies for diseases of the eye.
Gene Sciences, Inc.
Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Uniquity Bio
Uniquity Bio operates as a drug development company.
Tavec pharma
Tavec Pharmaceuticals is developing injectable therapies to treat cancers.
More informations about "Artgen Therapeutics"
Artgen biotech - Group Structure
Organization of wholesale sales and drugs for the Artgen group company. ... ArtGene Therapeutics ... [email protected] +7 (495) 646-80-76 ©2003-2025 Artgen biotech About the …See details»
ArtGene Therapeutics - Artgen biotech
ArtGene Therapeutics is a partner company that holds an intellectual property license for the Neovasculgen drug and developments created outside the Russian Federation and the CIS. ...See details»
Artgen Therapeutics - Crunchbase Company Profile
Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101, is a DNA plasmid designed …See details»
Artgen Biotech is a biotechnology company
Artgen is a biotechnology company bringing to healthcare a portfolio of innovative platform developments. About It includes companies of different development stages: from seed to …See details»
Artgen Company Profile 2024: Valuation, Funding & Investors
Artgen General Information Description. Provider of biotechnology services based in Rockville, Maryland. The company specializes in providing biotechnology services including …See details»
ArtGen - Products, Competitors, Financials, Employees, …
About ArtGen. Developer of a gene therapy drug. The company has been licensed the exclusive U.S. and Canadian rights for Neovasculgen, first-in-class gene therapy drug that was …See details»
Артген биотех - биотехнологическая компания
[email protected] +7 (495) 646-80-76 ©2003-2025 Artgen biotech О компании ; Стратегия компании ...See details»
Artgen Therapeutics - Crunchbase
Artgen Therapeutics, Gene Sciences Inc., Anagin, Tavec Pharmaceuticals, Bikam, and BELX BioPharma are all involved in the biopharmaceutical industry. Artgen and Gene Sciences …See details»
ArtGene Therapeutics - Артген биотех
Разработчики: ArtGene Therapeutics Некстген Новости о компании . 26.12.2016. Пресс-релизы. Слияния и поглощения: ИСКЧ стал акционером американской компании Аrtgen, …See details»
Organization: Artgen Biotech - Cbonds.com
Organization: Artgen Biotech TIN 7702508905, PSRN 1037789001315 ... Artgen Biotech is a Russian public biotech company which is engaged in drug discovery, R&D and marketing of …See details»
Artgen biotech 2025 Company Profile: Stock …
Artgen biotech General Information Description. Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary …See details»
ArtGene Therapeutics - Артген биотех
ArtGene Therapeutics 是拥有与涅奥瓦斯库尔根药物相关并在俄罗斯联邦和独立国家联合体之外开发的知识产权许可的一家合作公司。该公司进行临床前和临床检验，开发ART-101药物，这是 …See details»
Artgen biotech - About the Company
Artgen is a biotechnology company with a portfolio of developments whose goal is to create, develop, and implement in medical practice innovative drugs, devices or treatment, …See details»
Artgen Biotech - 2025 Company Profile & Competitors - Tracxn
Mar 4, 2025 Artgen Biotech - Company developing biomedical products, including vaccines, antibodies, and gene therapy drugs. Artgen Biotech has 432 competitors. JavaScript is …See details»
Human Stem Cells Institute to develop ischemia drug in U.S. and …
Oct 12, 2016 * Says it has licensed the exclusive U.S. and Canadian rights for Neovasculgen to ArtGen, Inc., a privately held biotechnology company located in Rockville, MDSee details»
Артген биотех - Препараты – Артген биотех
Разработчик: ArtGene Therapeutics , Некстген ... [email protected] +7 (495) 646-80-76 ©2003-2025 Artgen biotech О компании ; Стратегия компании ...See details»
Nextgen
The action of the drug is fundamentally different from all known drugs for the treatment of chronic lower limb ischemia (CLI). This is the world’s first gene therapy drug based on the “therapeutic …See details»
Preclinical concept studies showing advantage of an inhaled
1 day ago Inhaled therapeutics have high potential for the treatment of chronic respiratory diseases of high unmet medical need, such as idiopathic pulmonary fibrosis (IPF). Preclinical …See details»
Human Stem Cells Institute to develop ischemia drug in U.S. and …
Oct 13, 2016 Human Stem Cells Institute Says it has licensed the exclusive U.S. and Canadian rights for Neovasculgen to ArtGen, Inc., a privately held biotechnology company located in …See details»
Artgen biotech - Drugs – Artgen biotech
Developer: ArtGene Therapeutics , Nextgen . Genotarget. Development of gene therapy drugs for the treatment of rare neuromuscular diseases. Drug. Indication. DSCVRY. Preclinical ...See details»